Primary mediastinal large B-cell lymphoma (MLBCL) shares important clinical and molecular features with classical Hodgkin lymphoma, including nuclear localization of the c-REL NF B subunit in a pilot series. Herein, we analyzed c-REL subcellular localization in additional primary MLBCLs and characterized NF B activity and function in a MLBCL cell line. The new primary MLBCLs had prominent c-REL nuclear staining and the MLBCL cell line exhibited high levels of NF B binding activity. MLBCL cells expressing a super-repressor form of I B had a markedly higher rate of apoptosis, implicating constitutive NF B activity in MLBCL cell survival. The transcriptional profiles of newly diagnosed primary MLBCLs and DLBCLs were then used to characterize the NF B target gene signatures of MLBCL and specific DLBCL subtypes. MLBCLs expressed increased levels of NF B targets that promote cell survival and favor antiapoptotic TNF signaling. In contrast, "ABC-like" DLBCLs had a more restricted, potentially developmentally regulated, NF B target gene signature. Of interest, the newly characterized "Host Response" DLBCL subtype had a robust NF B target gene signature which partially overlapped that of primary MLBCL. In this large series of primary MLBCLs and DLBCLs, NF B activation was not associated with amplification of the c-REL locus, suggesting alternative pathogenetic mechanisms.
Introduction
The Given the known role of the NF B survival pathway in cHL [9] [10] [11] and the striking similarities between the cHL and MLBCL transcriptional profiles, including upregulation of specific NF B target genes, we assessed the subcellular localization of c-REL in a small pilot series of primary MLBCLs 2 . In almost all cases, the c-REL NF B subunit was localized to the nucleus, underscoring the potential role of constitutive NF B activation in primary MLBCLs 2 .
Previous studies also implicate NF B signaling in the survival of a subset of DLBCLs. DLBCLs are thought to arise from normal antigen-exposed B-cells that have migrated to or through germinal centers (GC) in secondary lymphoid organs 12 . A series of recent profiling studies highlighted the similarities between subsets of DLBCL and their putative normal B-cell counterparts. These DLBCL subsets shared certain features with normal GC B-cells ("GC-type") or in vitro activated peripheral blood B-cells ("ABC-type"); an additional group of tumors ("Type 3" or "Other") could not be classified by cell of origin (COO) 4, 5 . In associated functional analyses, DLBCL cell lines with "ABC-type" signatures had high levels of NF B activity and increased sensitivity to NF B inhibition, specifically implicating the NF B survival pathway in this DLBCL subset 13 .
More recently, our group utilized a large series of newly diagnosed DLBCLs, whole genome arrays and multiple clustering methods to identify 3 robust DLBCL subtypes with unique comprehensive transcriptional signatures --"Oxidative Phosphorylation", "B-cell Receptor/Proliferation" and "Host Response" (HR) 6 . HR tumors have increased expression of T/NK-cell receptor and activation pathway components, complement cascade members, macrophage/dendritic cell markers and inflammatory mediators; these tumors also contain significantly higher numbers of CD2+/CD3+ tumor-infiltrating lymphocytes and interdigitating S100+/GILT+/CD1a-/CD123-dendritic cells 6 . HR DLBCLs share features of histologically defined T-cell/histiocyte-rich LBCL, including fewer genetic abnormalities, and presentation in younger patients with frequent splenic and bone marrow involvement 6 . To date, the potential role of NF B activation in HR tumors and the additional comprehensive clusters (CC) has not been defined.
In LBCLs with likely NF B activation, the genetic bases for constitutive NF B signaling are not yet known. In cHL, gains of chromosome 2p12-16 (the c-REL locus) have been associated with the accumulation of nuclear c-REL, suggesting that c-REL amplification leads to increased NF B activity 9 . A small number of DLBCLs and MLBCLs also have gains of chromosome 2p12-16, prompting speculation regarding a similar mechanism of NF B activation in LBCLs 14, 15 .
However, recent studies suggest that c-REL amplification is: 1) more common in "GC-type" DLBCLs than "ABC-type" DLBCLs 4 ; and 2) infrequently associated with nuclear c-REL expression 16 .
Given the likely role of NF B in promoting normal and malignant B-cell survival, the NF B pathway includes promising rational therapeutic targets 17 . For these reasons, we have analyzed the role of NF B activation in MLBCL and DLBCL subtypes using a combination of c-REL immunolocalization, molecular inhibition of NF B in informative cell lines and analyses of NF B target gene signatures and c-REL amplification in well-defined primary LBCLs.
Materials and Methods

Cell lines
The Karpas 1106 MLBCL cell line (gift of A. Karpas, Cambridge, UK 18 ), two DLBCL cell lines (DHL6 and OCI-LY10; 19 ) and a Hodgkin's lymphoma cell line 
Microarray analysis: Description of dataset
The expression of NF B target genes in primary large cell lymphomas was evaluated using a recently described dataset of 176 DLBCL and 34 MLBCL transcriptional profiles 2,6 (URL:http://www.broad.mit.edu/cgi-bin/cancer/datasets).
All primary DLBCL and MLBCL tumor specimens were nodal or mediastinal biopsies from newly diagnosed, previously untreated patients. The dataset included the top 15,000 genes from the Affymetrix U133A/U133B arrays, ranked using a median absolute deviation (MAD) variation filter across all samples 2 .
The DLBCL tumor samples were previously assigned to the developmentally related "cell-of-origin" (COO) categories "Germinal Center B-cell-like" (GCB),
"Activated B-cell-like" (ABC), and "Other" using linear predictive scores 5, 6 . The DLBCL tumor samples were also assigned to the more recently described comprehensive consensus clusters, "Oxidative Phosphorylation" (OXP), "B-cell receptor signaling/ proliferation" (BCR), and "Host Response" (HR) 6 .
Curation of microarray-based NF B target gene sets
Three NF B target gene sets were selected for detailed analysis based on the gene sets' relevance to the biology of normal and malignant B-cells: (Geneset 1)
NF B target genes that were downregulated in Hodgkin's lymphoma cell lines following introduction of NF B super-repressor I B N 11 ; (Geneset 2) Previously described NF B target genes that were differentially expressed at specific stages of normal B-cell development and/or in DLBCLs with "ABC" features 13, 24 (Geneset 3) NF B target genes that were downregulated after siRNA silencing of REL-A (p65) in TNF -stimulated HeLa cells 25 . The complete gene sets and their associated microarray probe sets are included in the Supplementary Information.
Enrichment test for NF B genes in MLBCL.
Gene Set Enrichment Analysis (GSEA) 2,6,26 was performed as previously 
Quantitative PCR analysis of c-REL amplification
Quantitative PCR was used to measure c-REL copy numbers in genomic DNA isolated using a published method 27 . In brief, real-time PCR was performed using the ABI Prism 7700 sequence detector system (Applied Biosystems, Foster City, CA). C-REL copy numbers were compared to those of two control genes were considered positive for c-REL amplification.
Results
Confirmation of nuclear subcellular localization of c-REL in MLBCL
To confirm and extend our original observations regarding c-REL nuclear localization in MLBCL, we analyzed a new series of primary tumors with a robust c-REL immunohistochemical assay. As before, there was prominent c-REL nuclear staining in 7/7 new primary MLBCLs (Fig. 1 ). c-REL staining intensity and subcellular localization were more variable in DLBCLs, consistent with recent observations 16 . Karpas 1106 cells (Fig. 2D) . The difference between SR-I B transduced MLBCL cells and either empty vector expressing or parental cells was significant (p < 0.0001 in each case), whereas there was no difference between empty vector and parental cells (p = N.S.). Taken together, these data indicate that constitutive NF B activity is essential for the survival of this MLBCL cell line.
Fig. 1 : Subcellular localization of c-REL in MLBCL. A) Prominent intense c-REL nuclear staining in a representative primary MLBCL. B) Variable c-REL staining intensity and subcellular localization in a DLBCL. Original magnification 400X.
NF B activity is required for cell survival of a MLBCL cell line
Fig. 2: NF B activity and inhibition in a MLBCL cell line. A) NF B DNA-binding activity of the MLBCL cell line, Karpas 1106, two DLBCL cell lines, OCI LY10 and DHL6, and a Hodgkin's lymphoma cell line, KM-H2. NF B DNA binding activity was measured using a colorimetric assay. Measurements were performed in triplicates. B) NF B activity and apoptosis in MLBCLs expressing an I B superrepressor. Left panel) NF B DNA-binding activity in MLBCL cells transduced with MSCV-eGFP (vector) alone or MSCV-eGFP-SR-I B . Measurements were performed in triplicates. NF B activity was significantly lower in SR-I B cells than in vector -only cells (p<.0001, one-sided student's t-test). Right panel) The apoptotic fraction (percentage Annexin V+ GFP+) of cells transduced with MSCV-eGFP-SR-I B is much higher than that of cells transduced with vector alone. C) Apoptosis in MLBCL cells expressing an I B super-repressor. GFPpositive cells expressing vector alone or MSCV-eGFP-SR-I B were analyzed for expression of Annexin V (Alexa 568). GFP, x-axis, Annexin V, y-axis. D) Proliferation of MLBCL cells expressing an I B super-repressor. The proliferation (MTS absorbance) of parental and GFP+ vector only and MSCV-eGFP-SR-I B transduced MLBCL cells was measured at 0, 24, 48 and 72 hours and assessed with an ANOVA model which included the type of treatment and time of measurement. The difference between SR-I B transduced MLBCL cells and either vector -only or parental cells was significant (p <.0001 in each case), whereas there was no difference between empty vector and parental cells (p = N.S.). The measurements were performed in triplicates. All experiments (A-D) were performed 3-4 times with comparable results; representative experiments are shown.
The primary MLBCL signature is enriched for NF B target genes
After demonstrating the importance of NF B activity for the proliferation and viability of a MLBCL cell line, we assessed the consequences of NF B activation in our series of primary MLBCLs with available transcriptional profiles.
Specifically, we asked whether previously defined, co-regulated sets of NF B target genes were upregulated in primary MLBCLs (as compared with DLBCLs) using gene set enrichment analysis (GSEA). Three independently defined sets of NF B target genes with likely biologic relevance in MLBCL were used: two series of target genes responsive to NF B inhibition in Hodgkin's lymphoma cell lines and TNF-stimulated adherent cells, respectively 11, 25 ; and an additional series of previously described NF B targets that were differentially expressed in in vitro activated normal peripheral blood B-cells and "ABC-like" DLBCLs 13, 24 . The primary MLBCL signature was significantly enriched for the credentialed NF B targets from Hodgkin's lymphoma cell lines (Geneset 1, p = .05) and the likely NF B targets in normal activated B-cells and "ABC-like" DLBCLs (Geneset 2, p = .02). In addition, there was a trend toward more abundant TNF-induced NF B target transcripts in primary MBLCLs (Geneset 3, p = .08).
MLBCL are characterized by a broad NF B activation signature
Given the partial overlap between the above-mentioned series of NF B target genes, we then combined the NF B target gene sets for more detailed analyses of NF B activation signatures in primary MLBCLs and previously defined subsets of DLBCL. A large series of NF B targets were expressed at significantly higher levels in MLBCL than DLBCL (Fig. 3A) , including genes regulating cell viability To compare the NF B target gene signature of MLBCL with that of "ABC-like" DLBCLs, we also identified the differentially expressed NF B target genes in "ABC-like" vs. "non-ABC-like" DLBCL ( Fig. 3B ). Not surprisingly, the "ABC-like" DLBCLs in our series had more abundant expression of previously described ABC NF B targets including BCL-2, IRF4, cyclin D2 and CD44. However, there was a much smaller series of abundant NF B targets in ABC-like DLBCLs and only limited overlap with the NF B activation signature in primary MLBCLs (compare Figs. 3A, B and D) .
Fig. 3: Differential expression of NF B target genes in large B-cell lymphoma subtypes. NF B target genes that met the 99 th percentile of the permutation distribution and exhibited a > 30% difference in median expression values were considered to be differentially expressed. Differentially expressed NF B target genes in: A) primary MLBCL vs. DLBCL; B) "ABC-like" DLBCLs vs. "GCB-like"
and "Other" DLBCLs; and C) "HR" DLBCLs vs. "OxPhos" and "BCR/Proliferation" DLBCLs. D) Comparison of the NF B target gene signatures from primary MLBCL, "HR" DLBCLs and "ABC-like" DLBCLs.
Confirmation of NF B activation signature in MLBCL in independent dataset
We next assessed the reproducibility of the identified NF B target gene signatures in MLBCL and DLBCL subsets using an independent series of primary tumors (38 MLBCLs and 13 "ABC-like" and 13 "GC-like" DLBCLs) with publicly available transcriptional profiles 3 Fig. 3 . A) MLBCLs vs. DLBCLs. (This independent series of primary MLBCLs had significantly higher expression of 79% (26/33 of the NF B target genes that were identified in our series and represented on both platforms); and B) "GC-type" vs "ABC-like" DLBCLs. The independent data set includes all primary MLBCLs (38 tumors) and DLBCLs (26 tumors,13 "GC-type" and 13 "ABC-like) that were made available at http://llmpp.nih.gov/PMBL/ (Supplementary Information of Ref. 3 ). These data suggest that the consequences of NF B activation may vary in tumors with different developmental features and specific microenvironmental signals (Fig. 3D ). were also expressed at high levels in normal "in vitro activated" B-cells 24 , suggesting that these targets may be developmentally regulated in this LBCL subset.
Fig. 4: Differential expression of NF B target genes in an independent series of primary MLBCLs and DLBCLs (Ref. 3 ). Differentially expressed NF B target genes were defined as in
Amplification of the c-REL locus is associated with high c-REL transcript abundance, but not with a NF B activation signature
Discussion
In contrast to primary MLBCLs, "ABC-like" DLBCLs did not exhibit consistent nuclear localization of c-REL-containing heterodimers, prompting speculation that additional NF B heterodimers may be active in these tumors. Consistent with this possibility, "ABC-like" DLBCL cell lines were previously reported to have p50/REL-A DNA binding activity in addition to p50/c-REL heterodimers 13 . Given the unique characteristics of the "ABC-like" NF B target gene signature, these data suggest that NF B activation may be associated with different combinations of NF B heterodimers and signaling molecules in discrete LBCL subtypes.
In addition to characterizing the NF B target gene signatures of primary MLBCL and ABC-type DLBCLs, we identified a robust NF B target gene signature in "HR" DLBCLs. "HR" DLBCLs and primary MLBCLs share certain features including a brisk host inflammatory infiltrate and increased expression of associated NF B target genes (CCL2 (MCP1), CCL3 (MIP1 ), SDC4 41 , PECAM 42 , SOD2 33 , Fig. 3D ). Like primary MLBCLs and "ABC-like" DLBCLs, HR DLBCLs also had increased expression of c-FLIP, underscoring its potential importance in each tumor type. Consistent with the specific characteristics of the T/NK-cell rich inflammatory infiltrate in HR DLBCLs, these tumors also had increased expression of NF B targets potentially derived from infiltrating activated T/NK cells (IL15R 43 and NK4, Fig. 3D ).
Given the prominent host inflammatory responses in primary HR DLBCLs and
MLBCLs, it is of interest that the LBCLs express NF B targets which may limit the effectiveness of host immune responses (HLA-F and CCL22, Fig. 3D ).
Although HLA-F has limited tissue distribution, this atypical HLA class 1 molecule is expressed on B lymphoblastoid and monocytoid cell lines 44 . Recent reports suggest that HLA-F interacts with the inhibitory counter-receptors, ILT2 and ILT4, potentially limiting associated T and NK cell responses 45, 46 . The chemokine, CCL22 (MDC), which is expressed by macrophages, dendritic cells and certain tumors (including Hodgkin's lymphoma), attracts CCR4+ T regulatory cells into secondary lymphoid organs and areas of inflammation and limits host anti-tumor immune responses [47] [48] [49] .
After implicating the NF B cell survival pathway in primary MLBCLs and characterizing the NF B target gene signatures in primary MLBCLs and "ABClike" and HR DLBCLs, we assessed the role of c-REL amplification in these tumors. Consistent with recent reports 4 , we found that c-REL amplification was more common in "GC-like" DLBCLs than in LCL subtypes with evidence of NF B activation. In our series, only 1 of 34 primary MLBCLs had amplification of the c-REL locus, although all analyzed tumors had nuclear accumulation of c-REL and NF B target gene upregulation. Taken together, these data suggest that amplification of the c-REL locus is not the pathogenetic mechanism associated with NF B activity in LBCL subtypes and that additional gene(s) at 2p12-16 may contribute to the observed "GC" subtype.
The current studies define a role for NF B-mediated tumor cell survival in primary MLBCL and identify an overlapping NF B target gene signature in the newly characterized HR DLBCLs. In addition, the studies delineate important differences between the shared NF B target gene signature in primary MLBCLs and HR tumors and the more restricted, potentially developmental NF B signature in ABC-type DLBCLs. In addition to providing specific insights regarding similarities and differences in NF B signaling in these tumors, the data will guide our attempts to pharmacologically manipulate the NF B pathway in these diseases 50 .
